In the BioHarmony Drug Report Database

"Preview" Icon

Brentuximab vedotin

Adcetris (brentuximab vedotin) is an antibody pharmaceutical. Brentuximab vedotin was first approved as Adcetris on 2011-08-19. It is used to treat hodgkin disease and large-cell lymphoma immunoblastic in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against tumor necrosis factor receptor superfamily member 8.

 

Trade Name

 

Adcetris
 

Common Name

 

brentuximab vedotin
 

ChEMBL ID

 

CHEMBL1742994
 

Indication

 

hodgkin disease, large-cell lymphoma immunoblastic, non-hodgkin lymphoma
 

Drug Class

 

Synthetic analogs of the dolastatin series; monoclonal antibodies: chimeric, tumors as target

Image (chem structure or protein)

Brentuximab vedotin structure rendering